Gemcitabine and CT-011 for Resected Pancreatic Cancer
- Many doctors believe that individuals who have had surgery to remove pancreatic cancer should receive additional treatment, known as adjuvant therapy or adjuvant treatment, to prevent the cancer from returning. One chemotherapy drug that has been found to be effective in some patients with pancreatic cancer is called gemcitabine; it has been shown to improve patient survival by 6 months. Researchers are searching for new drugs or drug combinations to improve on these results.
- Some chemotherapy drugs kill cancer cells directly, but appear to prevent the immune system from helping in that fight. The experimental drug CT-011 is designed to help the immune system remain active to fight cancer cells. CT 011 has been tested in laboratories and studied for use with a number of other cancers, but it has not been given in combination with gemcitabine as a treatment for pancreatic cancer.
- To test the safety and effectiveness of chemotherapy drugs gemcitabine and CT-011 as a follow-up treatment for pancreatic cancer that has been surgically removed.
- Individuals at least 18 years of age who have had surgery to remove pancreatic cancer and have not had other types of follow-up treatments.
- Participants will be screened with a full medical history and physical examination, blood and urine tests, and imaging studies.
- Participants will receive gemcitabine and CT-011 in 28-day cycles of treatment.
- Participants will receive CT-011 on the first day of every 28-day cycle. One week later (Day 8), participants will receive gemcitabine, and will have two additional doses of gemcitabine in the following 2 weeks (days 15 and 21).
- Participants will be monitored with frequent blood and urine tests throughout their treatment visits. Every other cycle (about every 2 months), participants will also have imaging studies to evaluate the experimental treatment.
- Participants who do not have serious side effects and remain cancer-free may receive this drug combination every 28 days for a total of 6 cycles.
- Participants will have follow-up visits with additional blood tests (including apheresis to collect red blood cells) every 2 months after stopping treatment for up to 2 years.
Cancer of the Pancreas
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Pilot Study to Test the Feasibility of the Combination of Gemcitabine and Anti-PD1 Monoclonal Antibody (CT-011) in the Treatment of Resected Pancreatic Cancer|
- To determine the feasibility and safety of the combination of CT-011 and Gemcitabine in patients after primary macroscopic resection of pancreatic adenocarcinoma. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
- To determine if the addition of CT-011 to Gemcitabine can improve the median disease-free survival (DFS) in resected pancreatic cancer. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
|Study Start Date:||September 2012|
|Estimated Study Completion Date:||February 2017|
|Estimated Primary Completion Date:||February 2014 (Final data collection date for primary outcome measure)|
Experimental: Single arm
Combination CT-011 and Gemcitabine
3mg/kg, intravenous (IV) day 1 of each cycle over 2 hours. (Must be administered at the National Institutes of Health (NIH))Drug: Gemcitabine
1000mg/m^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle (This infusion may be administered at local oncologist office or the National Institutes of Health (NIH))
- In 2009, 49,096 patients were diagnosed with pancreatic cancer. Pancreatic cancer carries a poor prognosis with an overall 5-year relative survival rate of 5.6%.
- One of the leading causes for immune suppression in cancer patients was suggested to be associated with the elevated expression of programmed cell death 1 ligand 1 (PD-L1) human B7 homolog 1 (B7-H1) at tumor-involved sites, either by the tumor itself or by surrounding cells like regulatory immune cells, resulting in the local suppression and apoptosis of tumor infiltrating effector lymphocytes.
- CT-011 is a humanized immunoglobulin G 1 (IgG1) kappa recombinant monoclonal antibody against PD-1 receptor that blocks the interaction of PD-L1 with PD-1. CT-011 specifically binds to an epitope that is shared between the murine and the human PD-1 receptors on activated T cells, B cells, natural killer (NK) cells, and myeloid cells (CD14+ cells) and primarily functions in effector/memory T lymphocytes and in NK cells. In a functional bioassay, CT-011 was demonstrated to block the activity of PD-1 and to operate on CD4+CD45RO+ effector/memory T lymphocytes leading to attenuation of apoptotic processes.
- CT-011 was studied in experimental murine tumor models of melanoma, lung cancer, fibrosarcoma, leukemia/lymphoma and colorectal carcinoma and was shown to inhibit tumor growth and extend the survival of tumor-bearing nude mice, and to generate tumor-specific protection against tumor re-challenge.
- Recent findings have demonstrated that chemotherapies like paclitaxel, etoposide or fluorouracil (5-FU) induce the expression of the PD-L1 on tumor cell lines leading to an immune-suppressive environment and promoting PD-L1-mediated T cell apoptosis
- Primary endpoint: To determine the feasibility and safety of the combination of CT-011 and Gemcitabine in patients after primary macroscopic resection of pancreatic adenocarcinoma.
- Secondary endpoint: To determine if the addition of CT-011 to Gemcitabine can improve the median disease-free survival in resected pancreatic cancer.
- Adult patients with histologic verification of adenocarcinoma of the pancreas (T1-3, N0-1) who have undergone surgical resection within the past 4-8 weeks.
- Must meet all laboratory safety criteria and not have active or history of autoimmune disease or conditions, be treated with immunosuppressive drugs, or require the use of systemic steroids.
- Pregnant or nursing women will be excluded. Subjects with active infection, human immunodeficiency virus (HIV), Hepatitis B or C will be excluded.
- Eligible subjects will receive adjuvant combination CT-011 and Gemcitabine.
- Gemcitabine will be given at a dose of 1000mg/m^2 by intravenous infusion over 30 minutes on Days 8, 15 and 22 of each cycle.
- CT-011 will be given at a dose of 3mg/kg by intravenous infusion over 2 hours on day 1, one week prior to the first Gemcitabine infusion of each cycle.
- Treatment will be continued for a total of 6 cycles or until disease recurrence or grade IV non-hematological toxicity if occurred before the completion of 6 cycles.
- The study will be conducted as an optimal two-stage phase II trial, in order to rule out an unacceptably low 50% of patients who do not receive the full dose of CT-011 (p0=0.50) in favor of a modestly high 80% fraction who receive the full dose of CT-011 (p1=0.80). It is anticipated that up to 32 patients may be enrolled onto this trial.
|Contact: Pam Bourbo, RNfirstname.lastname@example.org|
|United States, Georgia|
|Georgia Health Sciences University||Not yet recruiting|
|Augusta, Georgia, United States, 30912|
|Contact: Pam Bourbo, RN 706-721-2730 email@example.com|
|Sub-Investigator: Asha Nayak, MD|
|Principal Investigator: Samir N. Khleif, MD|
|Sub-Investigator: Paul Bilodeau, MD|
|Sub-Investigator: Paul Dainer, MD|
|Sub-Investigator: Russell Moores, MD|
|Principal Investigator:||Samir N. Khleif, MD||Georgia Regents University|